Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptive Biotechnologies Corporation (ADPT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, commercial-stage biotechnology company, Adaptive Biotechnologies uses these filings to report financial results, material agreements, and other significant corporate events related to its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Among the key documents are current reports on Form 8-K, which the company files to furnish earnings press releases and to describe material events. For example, Adaptive Biotechnologies has filed Form 8-K reports to present quarterly financial results, including segment revenue for its MRD and Immune Medicine businesses, and to disclose the termination of a Strategic Collaboration and License Agreement with Genentech, Inc. related to cancer cell therapy research and development. These filings may also outline expected accounting impacts, such as recognition of remaining non-cash revenue from prior collaboration payments.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for more detailed information on revenue composition, operating expenses, segment performance, risk factors, and management’s discussion and analysis. For a company like Adaptive Biotechnologies, these periodic reports help explain how its clonoSEQ MRD business and Immune Medicine programs contribute to overall results, as well as how it manages cash burn targets and investment in research and development.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight the main points of each filing. Users can quickly see which filings relate to earnings announcements, collaboration changes, or other material events, and can use the underlying documents to analyze ADPT’s financial condition, strategic focus, and progress in MRD and immune medicine initiatives.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a mix of option exercises and share sales. Over April 22–24, 2026, she exercised stock options covering 44,166 shares of Common Stock at an exercise price of $8.46 per share and sold 57,180 shares in open-market transactions at weighted average prices around $14 per share, as detailed in price ranges in the footnotes. After these transactions, she directly holds 382,132 shares of Common Stock and 60,438 stock options. The filing notes that all transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
Adaptive Biotechnologies Corporation is asking shareholders at its virtual 2026 annual meeting on June 5, 2026 to elect two Class I directors, approve 2025 executive pay on an advisory basis, and ratify Ernst & Young LLP as auditor for 2026.
The proxy highlights 2025 revenue of $277.0 million versus $179.0 million in 2024, driven by minimal residual disease revenue of $212.3 million and 105,587 clonoSEQ tests. Net cash used in operations fell to $46.0 million from $95.2 million, and cash, cash equivalents and marketable securities were $227.2 million as of December 31, 2025.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of pre-planned stock transactions in common stock. Under a Rule 10b5-1 trading plan, she exercised stock options to acquire a total of 56,047 shares at exercise prices of $8.46 and $12.14 per share, then sold 69,061 shares in open‑market transactions at weighted average prices in the mid‑$14 range. Following these exercises and sales, she continues to hold a substantial direct ownership position in Adaptive Biotechnologies common stock.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and share sales in Adaptive Biotechnologies Corp. Between April 14 and April 16, 2026, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $8.46 per share.
Over the same period, she sold 57,180 shares of common stock in open-market transactions, including sales reported at weighted average prices of $14.18, $14.61 and $14.56 per share. These transactions were carried out under a Rule 10b5-1 trading plan adopted on November 18, 2025. Following the transactions, she directly holds 408,160 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and related stock sales. She exercised options to acquire 44,166 shares of common stock at exercise prices of $7.27 and $8.46 per share, then sold 57,180 shares in open-market transactions at weighted average prices generally in the mid‑teens per share. These trades, executed on April 9, 10, and 13, were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. After the transactions, Rubinstein directly owned 421,174 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo exercised stock options and sold shares in a planned transaction. On April 8, 2026, Lo exercised options to acquire 2,344 shares of common stock at $3.99 per share, then sold 22,564 shares of common stock in an open-market sale at a weighted average price of $15.07 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on September 15, 2025. After the transactions, Lo owns 271,154 shares directly and an additional 2,500 shares indirectly through a spouse.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported an open-market sale of 10,000 shares of common stock on April 8, 2026 at a weighted-average price of $14.85 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 11, 2025. Following this transaction, Robins directly holds 1,512,058 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported open-market sales of company common stock executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 11, 2025.
He sold 83,332 shares on April 6, 2026 at a weighted average price of $14.41 per share in multiple trades between $14.19 and $14.84. He then sold 37,263 shares on April 8, 2026 at a weighted average price of $15.19 per share, with individual trades between $15.00 and $15.53.
Across both transactions, Robins sold 120,595 shares and directly held 2,180,518 shares of Adaptive Biotechnologies common stock following the most recent sale.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and share sales in a planned series of trades. She exercised stock options for 56,047 shares of common stock at exercise prices of $7.27 and $12.14 per share and sold 69,061 shares in open‑market transactions at weighted average prices ranging from about $13.39 to $15.48 between April 6 and April 8, 2026. After these transactions, she directly held 434,188 shares of common stock and retained vested stock options representing 37,553 shares. The filing notes that all transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 18, 2025.